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Wegener’s granulomatosis of the pituitary gland resulting in diabetes insipidus is a rare complication of the disease. Standard
treatment for Wegener’s granulomatosis involves a combination of prednisolone and cylophosphamide, however biologic agents
are now being used in refractory cases. We report three cases of patients with diabetes insipidus as a complication of Wegener’s
granulomatosis who were treated with biologic agents. All three cases showed clinical response to treatment with biologic agents
including rituximab and alemtuzumab and two cases demonstrated improvement in pituitary gland abnormalities by MRI.
Clinicians should be aware that diabetes insipidus can present as a complication of Wegener’s granulomatosis and that biologic
therapies may be eﬀective in refractory cases.
Copyright © 2009 Joanna Rosalind Cunnington et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Wegener’s granulomatosis (WG) is a systemic, necrotizing,
granulomatous vasculitis of unknown aetiology. Diﬀuse
small and medium vessel involvement in WG can result in
a wide range of clinical manifestations, however classically
WG aﬀects the upper and lower respiratory tracts and
kidneys. Central nervous system (CNS) involvement in
WG is unusual, and diabetes insipidus (DI) secondary to
pituitaryinvolvement inWGisrare[1].Standardtherapyfor
aggressive WG remains a combination of prednisolone and
cyclophosphamide, a regime that has been shown to induce
remission and reduce mortality [2]. However not all patients
respond to this regime so alternative therapeutic options are
being investigated. In this report we present three cases of
DI secondary to WG that have required biologic therapies to
achieve remission.
2.Case1
A 19-year old man presented in July 2000 with recurrent
epistaxis, haemoptyis, nasal crusting, vasculitic skin rash,
and bilateral episcleritis. On admission he was systemically
unwell with a high ESR (113mm/h) and CRP (61mg/L).
Full blood count and renal function were normal. Chest
x-ray showed bilateral pulmonary cavities. Urinalysis was
positive for blood and protein. Cytoplasmic antineutrophil
cytoplasmic antibody (cANCA) was positive with a PR3
titre of 73 (normal <6). Skin biopsy was in keep-
ing with WG. Mycobacterial and fungal infection were
excluded.
He was started on intravenous pulses of cyclophos-
phamide alongside prednisolone (initially 40mg per day)
and co-trimoxazole. His disease rapidly responded. ESR
fell to 15mm/h, CRP to 22mg/dL, and PR3 cANCA titre
to 15. Urinalysis became negative, and chest x-ray showed
complete resolution of pulmonary cavities. He continued to
suﬀer low-grade nasal and sinus symptoms and, over the
next four years, received methotrexate (up to 25mg/week),
inﬂiximab (up to 5mg/kg 6 weekly), and mycophenylate
mofetil (1g twice daily), interspersed with further courses of
pulsed or oral cyclophosphamide and prednisolone. Despite
these measures, he continued to have clinically active ENT
disease, low-grade inﬂammatory markers, and MRI evidence
of gradually progressive destruction of sinuses and nasal
septum.2 International Journal of Rheumatology
In May 2005 he developed polyuria and polydypsia.
Investigations showed serum osmolarity of 303mosmol/kg
(normal up to 295) and urine osmolality of 75mosmol/kg
(normal 40–1200), serum creatinine 92µmoL and sodium
142mmol/L (urinary sodium not available). MRI scan
showed inﬂammation involving the sphenoid sinus and left
cavernous sinus, dural enhancement and inﬁltration, and
enlargement of the pituitary gland. Circulating levels of
anterior pituitary hormones were within normal limits. The
diagnosis of diabetes insipidus secondary to pituitary inﬁl-
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performed because of the striking clinical presentation and
the dramatic response to desmopressin (polyuria/polydypsia
resolved, serum and urine osmolarity returned to normal).
In view of the progression of the underlying WG despite
conventional therapies, he was treated with rituximab 1g
intravenously on two occasions 15 days apart. Mycopheno-
late mofetil was discontinued four weeks after the second
dose.Hereceivedasecondcycleofrituximab15monthsafter
the ﬁrst one for presumed neurological recurrence-memory
loss, sleep disturbance, and seizures, all of which later
improved. Repeat MRI scan done 17 months later showed
normalization of the previously described pituitary changes.
In addition there was no further progression of the disease in
thesinusesorintracranially.Theduralenhancementthatwas
seen earlier was also not seen now. A third MRI scan done
another 15 months on continues to be stable with normal
appearance of the pituitary. In this time there have been no
ﬂares of his systemic WG. The most recent investigations
show an ESR 11mm/h, CRP 3mg/dL and PR3 ANCA titre
of 12. Prednisolone dose has been reduced to 5mg daily.
He however continues to use desmopressin and sodium
valproate.
3.Case 2
A 33-year old female presented in 2002 with a 10 week
illness comprising bilateral otalgia, otorrhoea, hearing loss,
epistaxis, anorexia, and weight loss. On admission ESR was
84mm/h, CRP 224mg/L, and cANCA titre 1 in 160 (MPO
and PR3 not available). Haemoglobin and renal function
were normal. Urine dipstick was positive for blood and
protein. Chest x-ray was normal. A nasal biopsy revealed
extensive tissue necrosis, ﬂorid, active chronic inﬂammation
and widespread, and severe transmural active vasculitis
consistent with WG. She was treated for seven months
with oral prednisolone, oral cyclophosphamide (150mg
daily), and co-trimoxazole. Following clinical improve-
ment, she was converted to azathioprine and prednisolone
maintenance therapy. Her symptoms remained under con-
trol, and cANCA titre remained either negative or very
low.
In 2003 she presented with polyuria, polydypsia,
and severe frontal headache. There were no neurolog-
ical signs on examination. Investigations showed ESR
26mm/h, CRP 10mg/L, cANCA 1 in 80, serum sodium
141mmol/L, serum creatinine 87µmol/L, serum osmolal-
ity 300mosmol/kg, urinary sodium 58mmol/L, and urine
osmolality 110mosmol/kg. A water deprivation test showed
partial diabetes insipidus. The remaining pituitary assess-
ment was hampered by her prednisolone therapy and the
oral contraceptive pill. Prolactin and thyroid function were
normal. An MRI of the pituitary demonstrated a diﬀusely
enlarged gland containing a poorly enhancing lesion with
midline supra-sellar extension, consistent with WG. There
was loss of the usual high signal within the posterior gland
(Figure 1). She was diagnosed with diabetes insipidus sec-
ondary to WG and was initiated on long term desmopressin
which controlled the symptoms of diabetes insipidus. A
course of intravenous cyclophosphamide and methylpred-
nisolone was administered (monthly pulses of 15mg/kg and
10mg/kg, resp., for six months), and oral prednisolone was
increased to 60mg daily. Following this courseof treatmenta
repeatMRIshowedasmallbutdeﬁnitedecreaseinthesizeof
the pituitary lesion.
Over the next year immunosuppression comprised MMF
1g twice daily, oral prednisolone (reducing regime), and co-
trimoxazole.Whenherprednisolonedosewasreducedbelow
25mg daily, however, headaches recurred, and an MRI scan
revealedfurtherpituitaryenlargement,withaprominentlow
signal focus in the center, in addition to loss of high signal
in the posterior gland. ENT symptoms remained controlled
and inﬂammatory markers low with cANCA of 1 in 40.
Rituximab was administered in July 2005 as per case 1
and maintenance immunosuppression reduced to tapering
prednisolone. Headaches improved, and her disease was
subsequently managed with low-dose prednisolone (10mg)
monotherapy.Shehasreceived2furthertreatmentswithRit-
uximab, each 12 months apart, for recurrence of symptoms,
mainly headache, with good symptomatic improvement
each time. Maintenance prednisolone was continued. The
pituitary gland showed a reduction in size on MRI after the
second course of Rituximab.
4.Case 3
In 1995 a 26-year old man presented with malaise, nose
bleeds,andsinusitis.cANCAwas1in320(MPOandPR3not
available) and nasal biopsy consistent with WG, but no other
organ involvements were identiﬁed. He received 9 pulses
of IV cyclophosphamide (0.6mg per m2) over 15 months,
oral prednisolone, and co-trimoxazole. His disease remained
active, and he subsequently developed subglottic/right upper
lobe bronchus stenosis. In view of persistently active sinus
and upper airways disease, ultimately leading to nasal bridge
collapse, he received 6 courses of the humanised monoclonal
antilymphocyte antibody alemtuzumab between 1996 and
2002 as well as a short course of oral cyclophosphamide in
1999. His subglottic stenosis required steroid inﬁltration and
dilatation. His disease was subsequently controlled with a
small dose of prednisolone (9mg daily).
At routine follow-up in 2004 he gave an eight-month
history of “socially disabling” polyuria and polydypsia. Neu-
rological examination was normal. Investigations showed
ESR 10mm/h, CRP 19mg/L, cANCA 1 in 20, serum sodium
140mmol/L, serum creatinine 98µmol/L, serum osmolality
301mosmol/kg, and urine osmolality 139mosmol/kg (uri-
nary sodium not available). Anterior pituitary testing wasInternational Journal of Rheumatology 3
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Figure 1: (a) Sagital volumetric interpolated breath hold examination (VIBE) image demonstrating enlarged pituitary with loss of T1W
increased signal in the posterior pituitary lobe consistent with diabetes insipidus. (b) Coronal T1W image demonstrating the enlarged
pituitary in relation to the optic chiasm. OC : optic chiasm and P : pituitary.
within normal limits except TSH 0.05 mIU/L (on thyroxine
replacement).
MRI showed a diﬀusely enlarged pituitary and thickened
stalk consistent with inﬂammatory hypophysitis but no
enhancing lesion. There was extensive involvement of the
sphenoid sinus with inﬂammatory tissue and a perfo-
rated nasal septum. He was seen by an endocrinologist
and diagnosed with diabetes insipidus secondary to WG
and initiated on long term desmopressin which improved
his symptoms of diabetes insipidus. A further course of
alemtuzumab was administered. A subsequent MRI was
unchanged, but his ENT symptoms improved markedly.
Maintenance immunosuppression comprised MMF 1g twice
daily and prednisolone 20mg daily. MMF was discontinued
at the patient’s request in May 2005. In December 2005
ENT symptoms returned and MRI suggested progressive
sinus inﬂammation and further pituitary enlargement, for
which he received a further course of pulsed intravenous
cyclophosphamide and methylprednisolone. Subsequently
he received two courses of rituximab (each course 2 ×
1g iv, 15 days apart) to control progression of his
disease.
5. Discussion
Wegener’s granulomatosis is a systemic, necrotizing granulo-
matous vasculitis which can aﬀect virtually any organ in the
body. Involvement of the nervous system occurs in up to one
third of patients, the commonest neurological presentations
being peripheral neuropathies and mononeuritis multiplex.
CNS involvement is less frequent but has been documented
to cause cranial nerve palsies, cerebral vascular events, and
cerebral vasculitis [1]. Wegener’s granulomatosis aﬀecting
the posterior pituitary is rare with less than 50 cases
reported in the international medical literature since 1953,
and anterior pituitary involvement is even less common.
All three cases described in this report had predomi-
nantly ENT disease which remained variably symptomatic,
butpituitaryinvolvementdevelopeddespiteapparentdisease
control. In each case, posterior pituitary pathology was diag-
nosedfollowingdevelopmentofpolyuriaandpolydypsia.On
review of literature, the diagnosis of WG typically predates
the onset of diabetes insipidus, although hypopituitarism or
diabetes insipidus can be a presenting feature [3–8]. The
extent of systemic disease varies, and there is no clear pattern
which predisposes to pituitary involvement in WG: ENT
disease is not present in all cases.
Despite responding to therapy, most cases have an ongo-
ingrequirementfordesmopressin;anteriorpituitaryinvolve-
ment is similarly unlikely to recoverwith treatment.Anterior
pituitary function should be monitored in all patients with
posterior gland involvement, although assessment may be
hampered by corticosteroid therapy. Once anterior pituitary
dysfunction is diagnosed, it should be assumed that patients
are steroid dependent, and corticosteroid dose should fall no
lower than 7.5mg of prednisolone daily, or equivalent.
MRI of the pituitary is useful in diagnosis. The classic
MRI ﬁndings in WG are diﬀuse or focal infundibular thick-
ening and the absence of the normal high-intensity signal
in the posterior pituitary lobe, seen on T1-weighted images
(Figure 1)[ 9]. These MRI abnormalities may vary with
diseaseactivity[3,5, 7,10,11]. Only one of our cases showed
classical MRI abnormalities, which improved with initial
treatment. All three patients received either oral or pulsed
iv cyclophosphamide in conjunction with corticosteroids,
a regime which induces remission in up to 75% of WG
cases [2]. Twenty case reports of WG and DI were reviewed
in which, 12/20 patients received cyclophosphamide with
complete resolution of symptoms and signs of vasculitis.
5/20 had alternative regimes (prednisolone alone or with
methotrexate), and 3/20 were not published in the English
language. Cyclophosphamide has greatly reduced mortality4 International Journal of Rheumatology
in WG, but there are associated toxicities, not all patients
respond, and relapse occurs in some. A number of new
or experimental therapies have been advocated in such
cases [12]. Our three cases each received a biologic agent
for persistent disease or relapse. Rituximab is a chimeric
anti-CD20 monoclonal antibody (mAb) which depletes
B-lymphocytes but spares plasma cells. It was originally
developed for the treatment of B cell lymphomas but has
now been used to treat a variety of autoimmune conditions.
T h e r ea r ean u m b e ro fr e p o r t so fr i t u x i m a bb e i n gu s e dt o
treat WG with varying success [13–15]. Two of our cases
received rituximab with beneﬁcial outcome. Our third case
received several courses of alemtuzumab with improvement
on each occasion; subsequently he received rituximab for
relapsing disease following tapering of immunosuppression.
Alemtuzumab is a humanised anti-CD52 mAb which was
also initially developed for treatment of haematological
malignancy [16]. The CD52 antigen is abundantly expressed
on all lymphocytes, and at lower levels on monocytes.
Biologic therapies oﬀer a more targeted approach to disease
management of systemic vasculitis. Case series reveal a
potent eﬀect in refractory disease with an acceptable rate of
toxicity, although relapse can occur [17]. The eﬃcacy of this
approach alludes to the central role of lymphocytes (B and T
cells) in the disease process. Current trials are looking at the
earlier introduction of biologics in diseases such as WG.
In conclusion, diabetes insipidus resulting from WG is
an unusual, but well-described complication and clinicians
should have a high index of suspicion when patients
present with polyuria and polydypsia. We have presented 3
patients with established WG who subsequently developed
diabetesinsipidus.Allthreecaseswereresistanttotraditional
treatment but responded, in two cases robustly, to biologic
therapies.
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